Dr. Chau on Nivolumab in Asian Versus Western Patients With Gastric/GEJ Cancer

Ian Chau, MD, consultant medical oncologist, Royal Marsden Hospital, discusses the findings of an analysis of nivolumab (Opdivo) in Asian (Eastern) versus Western patients with gastric/gastroesophageal junction (GEJ) cancer.

Investigators assessed the safety profile of nivolumab in an analysis of cohorts from the ATTRACTION-2 and CheckMate-032 trials to compare outcomes between Eastern and Western patients with gastric/GEJ cancer when treated with immunotherapy.

In terms of treatment-emergent adverse events (AEs), Chau says that events were similar in the cohorts compare from ATTRACTION-2 and CheckMate-032. Per the analysis, Eastern and Western patients seemed to have the same AEs while on nivolumab, although the etiology and outcome of gastric/GEJ cancer differs between the 2 groups. Chau says that the time to AEs and duration are worth comparing, as well.